Matthew Roden, Aktis Oncology CEO
May 21, 2024 07:00 AM EDT
Startups
Deals

Lil­ly makes an­oth­er ra­dio­phar­ma move in col­lab­o­ra­tion with Ak­tis On­col­o­gy

Kyle LaHucik

Senior Reporter

Eli Lil­ly is again dip­ping in­to the buzzy area of ra­dio­phar­ma­ceu­ti­cals by way of pri­vate biotech Ak­tis On­col­o­gy.

The phar­ma gi­ant will dish out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Associate Director, Market Insights and Analytics

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Au­toim­mune CAR-T da­ta dump: Kyver­na, Ca­balet­ta shares fall af­ter un­veil­ing ear­ly-stage re­sults

Stephen Squin­to talks writ­ing checks and next-gen obe­si­ty drugs as JP Mor­gan clos­es first $500M+ biotech fund

Gilead can­cer drug ma­grolimab showed wor­ry­ing trends around death

AI drug dis­cov­ery start­up goes pub­lic in Hong Kong, nab­bing $115M to build on phar­ma part­ner­ships

Up­dat­ed: Telix Phar­ma­ceu­ti­cals pulls Nas­daq list­ing plans just be­fore trad­ing was to start

sponsored

De-risk­ing the pa­tient jour­ney in cell ther­a­pies: Six key con­sid­er­a­tions

A service from the Financial Times